Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Eli Lilly & Co., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Short-term borrowings and current maturities of long-term debt	5,117,100)	2,074,300)	5,161,600)	1,651,500)	6,904,500)	2,244,700)	661,600)	3,100)	1,501,100)	1,744,600)	2,121,800)	1,355,900)	1,538,300)	1,563,000)	1,778,500)	4,900)	8,700)	587,500)	1,263,800)	3,248,000)
Accounts payable	3,228,600)	2,886,500)	2,924,800)	2,473,700)	2,598,800)	2,435,100)	2,474,200)	2,015,900)	1,930,600)	1,683,200)	1,659,300)	1,433,300)	1,670,600)	1,566,800)	1,597,800)	1,639,600)	1,606,700)	1,430,100)	1,247,200)	1,207,700)
Employee compensation	2,093,900)	1,703,300)	1,168,300)	844,200)	1,650,400)	1,233,200)	867,700)	739,700)	1,059,800)	984,100)	835,800)	693,100)	958,100)	836,600)	755,500)	649,900)	997,200)	795,600)	673,600)	565,800)
Sales rebates and discounts	11,539,300)	12,429,700)	12,446,800)	9,429,600)	11,689,000)	11,522,300)	10,389,900)	9,529,500)	8,784,100)	8,568,400)	7,991,400)	6,768,700)	6,845,800)	7,185,600)	7,035,800)	5,821,400)	5,853,000)	5,745,200)	5,282,200)	4,703,900)
Dividends payable	1,346,300)	—)	1,170,500)	—)	1,169,200)	—)	1,016,200)	—)	1,017,200)	—)	882,200)	—)	885,500)	—)	770,800)	—)	770,600)	—)	—)	—)
Other current liabilities	5,051,400)	5,580,300)	4,249,200)	4,199,100)	3,281,300)	4,562,900)	3,505,400)	3,721,800)	2,845,400)	2,672,500)	2,130,100)	3,135,000)	3,154,400)	2,530,000)	3,154,800)	3,598,400)	3,245,400)	3,418,500)	3,521,700)	2,884,800)
Current liabilities	28,376,600)	24,674,100)	27,121,200)	18,598,100)	27,293,200)	21,998,200)	18,915,000)	16,010,000)	17,138,200)	15,652,800)	15,620,600)	13,386,000)	15,052,700)	13,682,000)	15,093,200)	11,714,200)	12,481,600)	11,976,900)	11,988,500)	12,610,200)
Long-term debt, excluding current maturities	28,527,100)	29,045,400)	23,730,400)	24,559,900)	18,320,800)	17,923,600)	18,158,400)	18,880,500)	14,737,500)	14,143,800)	14,692,000)	15,152,900)	15,346,400)	15,522,400)	14,736,600)	16,199,600)	16,586,600)	16,334,600)	15,064,400)	13,982,300)
Accrued retirement benefits	1,300,500)	1,448,500)	1,420,400)	1,427,900)	1,438,800)	1,311,900)	1,308,800)	1,313,000)	1,305,100)	1,832,500)	1,888,600)	1,940,300)	1,954,100)	3,878,800)	3,918,500)	3,969,800)	4,094,500)	3,435,500)	3,398,600)	3,632,000)
Long-term income taxes payable	4,060,900)	3,878,800)	3,496,600)	4,189,400)	3,849,200)	3,468,300)	3,330,700)	3,842,100)	3,709,600)	3,641,700)	3,557,600)	3,978,100)	3,920,000)	3,768,500)	3,738,000)	3,917,500)	3,837,800)	3,392,700)	3,377,500)	3,621,900)
Other noncurrent liabilities	2,178,200)	2,239,400)	2,470,700)	2,270,800)	2,240,600)	1,906,100)	1,951,800)	1,822,500)	1,824,000)	2,024,800)	2,645,600)	3,000,000)	3,378,000)	3,381,200)	3,659,200)	3,937,900)	3,807,400)	3,810,300)	3,866,000)	4,059,200)
Noncurrent liabilities	36,066,700)	36,612,100)	31,118,100)	32,448,000)	25,849,400)	24,609,900)	24,749,700)	25,858,100)	21,576,200)	21,642,800)	22,783,800)	24,071,300)	24,598,500)	26,550,900)	26,052,300)	28,024,800)	28,326,300)	26,973,100)	25,706,500)	25,295,400)
Total liabilities	64,443,300)	61,286,200)	58,239,300)	51,046,100)	53,142,600)	46,608,100)	43,664,700)	41,868,100)	38,714,400)	37,295,600)	38,404,400)	37,457,300)	39,651,200)	40,232,900)	41,145,500)	39,739,000)	40,807,900)	38,950,000)	37,695,000)	37,905,600)
Common stock	592,400)	593,900)	594,200)	594,200)	593,600)	593,600)	593,600)	593,500)	594,100)	594,100)	594,100)	594,100)	596,300)	598,200)	598,100)	599,700)	598,200)	598,100)	598,100)	598,100)
Additional paid-in capital	7,439,300)	7,339,600)	7,214,200)	7,009,500)	7,250,400)	7,160,000)	6,948,600)	6,793,100)	6,921,400)	6,829,000)	6,746,000)	6,656,300)	6,833,400)	6,758,000)	6,669,200)	6,579,200)	6,778,500)	6,698,800)	6,629,400)	6,556,100)
Retained earnings	13,545,000)	13,627,200)	13,178,000)	12,553,900)	10,312,300)	10,309,900)	10,368,500)	10,639,300)	10,042,600)	10,006,500)	8,556,000)	9,369,400)	8,958,500)	9,639,400)	8,530,100)	9,181,300)	7,830,200)	7,154,000)	6,617,200)	5,879,400)
Employee benefit trust	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)
Accumulated other comprehensive loss	(4,321,900)	(4,274,800)	(4,378,500)	(4,299,500)	(4,327,000)	(3,784,900)	(3,788,700)	(3,777,300)	(3,844,600)	(4,295,800)	(4,287,700)	(4,225,300)	(4,343,100)	(6,172,700)	(6,287,100)	(6,395,600)	(6,496,400)	(6,555,100)	(6,682,900)	(6,885,900)
Cost of common stock in treasury	(49,500)	(32,700)	(32,700)	(32,700)	(44,200)	(45,000)	(45,000)	(45,000)	(50,500)	(50,500)	(50,500)	(50,500)	(52,700)	(52,700)	(52,700)	(52,700)	(55,700)	(55,700)	(55,700)	(55,700)
Total Eli Lilly and Company shareholders’ equity	14,192,100)	14,240,000)	13,562,000)	12,812,200)	10,771,900)	11,220,400)	11,063,800)	11,190,400)	10,649,800)	10,070,100)	8,544,700)	9,330,800)	8,979,200)	7,757,000)	6,444,400)	6,898,700)	5,641,600)	4,826,900)	4,092,900)	3,078,800)
Noncontrolling interests	79,500)	80,700)	73,500)	85,200)	91,800)	87,000)	85,500)	104,500)	125,600)	95,800)	114,500)	131,200)	175,600)	197,100)	219,100)	200,600)	183,600)	169,100)	179,100)	118,400)
Total equity	14,271,600)	14,320,700)	13,635,500)	12,897,400)	10,863,700)	11,307,400)	11,149,300)	11,294,900)	10,775,400)	10,165,900)	8,659,200)	9,462,000)	9,154,800)	7,954,100)	6,663,500)	7,099,300)	5,825,200)	4,996,000)	4,272,000)	3,197,200)
Total liabilities and equity	78,714,900)	75,606,900)	71,874,800)	63,943,500)	64,006,300)	57,915,500)	54,814,000)	53,163,000)	49,489,800)	47,461,500)	47,063,600)	46,919,300)	48,806,000)	48,187,000)	47,809,000)	46,838,300)	46,633,100)	43,946,000)	41,967,000)	41,102,800)

Download chart

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Eli Lilly & Co. current liabilities decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 exceeding Q2 2024 level.
Noncurrent liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Eli Lilly & Co. noncurrent liabilities increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Eli Lilly & Co. total liabilities increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Total Eli Lilly and Company shareholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Eli Lilly & Co. total Eli Lilly and Company shareholders’ equity increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024.

Eli Lilly & Co. (NYSE:LLY)

Balance Sheet: Liabilities and Stockholders’ EquityQuarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data